TITLE

Flipside of the dialysis argument

AUTHOR(S)
DeSoto, Mark
PUB. DATE
November 2010
SOURCE
CMAJ: Canadian Medical Association Journal;11/23/2010, Vol. 182 Issue 17, p1886
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to the article "Access to treatment for multiple sclerosis must be based on science, not hope," by M. B. Stanbrook and P. C. Hébert in the 2010 issue.
ACCESSION #
55704057

 

Related Articles

  • IVIG trials in MS. Is albumin a placebo? Hommes, Otto; Haas, Judith; Soelberg-Sorenson, Per; Friedrichs, Mieke // Journal of Neurology;Feb2009, Vol. 256 Issue 2, p268 

    A letter to the editor is presented on the effects of intravenous immunoglobulin treatments for multiple sclerosis patients.

  • Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis. Haifeng Li; Xu Zhang // New England Journal of Medicine;5/6/2010, Vol. 362 Issue 18, p1738 

    A letter to the editor is presented in response to an article on the effects of cladribine in relapsing-remitting multiple sclerosis, by Giovannoni and colleagues.

  • Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis. Cohen, Jeffrey A.; Kappos, Ludwig // New England Journal of Medicine;5/6/2010, Vol. 362 Issue 18, p1738 

    A response by Cohen and Kappos to a letter to the editor about their article on the use of oral cladribine and fingolimod for multiple sclerosis relapse is presented.

  • Oral Cladribine and Fingolimod for Relapsing Multiple Sclerosis. Giovannoni, Gavin; Cook, Stuart; Sorensen, Per Soelberg // New England Journal of Medicine;5/6/2010, Vol. 362 Issue 18, p1738 

    A response by Giovannoni and colleagues to a letter to the editor about their article on the effects of cladribine in relapsing-remitting multiple sclerosis, is presented.

  • MULTIPLE SCLEROSIS TAKES VENOUS ROUTE: CCSVI AND LIBERATION THERAPY. Singh, Ajay Vikram // Indian Journal of Medical Sciences;Jul2010, Vol. 64 Issue 7, p337 

    A letter to the editor is presented in response to the article about multiple sclerosis (MS) treatment due Chronic Cerebro Spinal Venous Insufficiency (CCSVI).

  • Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis. Berger, Thomas; Deisenhammer, Florian // New England Journal of Medicine;10/20/2005, Vol. 353 Issue 16, p1744 

    A letter to the editor is presented in response to the article "Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple Sclerosis," by B.K. Kleinschmidt-DeMasters and K.L. Tyler in the July 28, 2005 issue.

  • Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis. Álvarez-Cermeño, José C.; Masjuan, Jaime; Villar, Luisa M. // New England Journal of Medicine;10/20/2005, Vol. 353 Issue 16, p1744 

    A letter to the editor is presented in response to the article "Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple Sclerosis," by B.K. Kleinschmidt-DeMasters and K.L. Tyler in the July 28, 2005 issue.

  • Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis. Kleinschmidt-DeMasters, B.K.; Tyler, Kenneth L. // New England Journal of Medicine;10/20/2005, Vol. 353 Issue 16, p1744 

    A response by B.K. Kleinschmidt-DeMasters and Kenneth L. Tyler to several letters to the editor in response to their article "Progressive Multifocal Leukoencephalopathy Complicating Treatment With Natalizumab and Interferon Beta-1a for Multiple Sclerosis" in the July 28, 2005 issue is presented.

  • Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis. Langer-Gould, Annette; Atlas, Scott W.; Pelletier, Daniel // New England Journal of Medicine;10/20/2005, Vol. 353 Issue 16, p1744 

    A response by Annette Langer-Gould, Scott W. Atlas and Daniel Pelletier to a letter on their article "Progressive Multifocal Leukoencephalopathy in a Patient Treated With Natalizumab" in the July 28, 2005 issue is presented.

  • Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Leussink, V.; Lehmann, H.; Meyer zu Hörste, G.; Hartung, H.-P.; Stüve, O.; Kieseier, B. // Journal of Neurology;Sep2008, Vol. 255 Issue 9, p1436 

    A letter to the editor is presented to report that rituximab was able to stabilize the condition of a patient suffering from fulminant multiple sclerosis who was not responding to natalizumab.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics